← Back
Data updated: Jun 28, 2026
CellTrans Inc.
Biotech Pharmaceuticals
CellTrans Inc. is a biotechnology company with 1 FDA-approved products.
2023
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
CellTrans Inc.'s Key Drugs
CellTrans Inc.'s core commercial portfolio centers on Lantidra — its most strategically important drugs approved in the last 15 years.
CellTrans Inc.'s Recent FDA Approvals
New NDA/BLA approvals for CellTrans Inc. over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
CellTrans Inc.'s Therapeutic Areas
Disease areas where CellTrans Inc. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
CellTrans Inc. Pipeline Snapshot
Active clinical trials for CellTrans Inc. across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Lantidra leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-06-27
- Latest
- 2023-06-27
- Applications
- 1